| | Therapeutic Sciences | | |
| | ChangeRemoveSave | Add | Add |
| School | University of Cambridge Postgraduate Study | | |
| Location | Cambridge, EGL, United Kingdom | | |
| School Type | Graduate School | | |
| School Size | Full-time Undergraduate: 12,850
Full-time Graduate: 11,600 | | |
| Degree | Master | | |
| Honours | | | |
| Co-op | | | |
| Length | 11 Month(s) | | |
| Entry Grade (%)* | | | |
| Prerequisites | | | |
| Prerequisites Notes | Bachelor degree (Honours) or 4 years Bachelor's without Honours or Baccalaureat / Bachelier (first-cycle degrees in Quebec province (3 years) (except McGill University)) or Bachelor degree (Honours) or Bachelor's without Honours (3-4 years with 120 credits) from McGill University or First Professional Degree / Grade Professionnelle (titles include Doctor of Dental Medicine / Surgery, Doctor of Medicine and Juris Doctor) with a grade of 3.3/4, 3.3/4.3, B+, 7/9 (York University) | | |
| Cost |
Tuition cost is converted from £31,332. | | |
| Scholarships | | | |
| Description | Students will develop an understanding of the mechanisms underlying normal function and subsequent dysfunction in human diseases and their amelioration or cure with advanced therapeutic regimes. The program provides students with all the tools and quantitative skills necessary to understand, develop and implement modern cutting-edge techniques in therapeutic sciences and cover the range of conventional and novel therapeutic modalities, including understanding biological pathways and therapeutic mechanisms, diagnostic and prognostic tools, identifying novel targets, and characterizing the pharmacologic profiles of new compounds, including adverse effects and toxicity. The close industry partner involvement in the development and delivery of the course sets it apart from others in the UK and indeed, internationally. Students will benefit greatly from the academic expertise and real-world insights which will be brought together in the proposed academic-industry partnership. The course covers conventional small molecule drugs and novel therapeutics approaches such as recombinant protein technologies, gene therapy, gene editing, cell-based therapies, regenerative medicine and electroceuticals. Students will also understand the social, financial, ethical, legal and policy implications of the introduction of these new therapies, and the course will link this training very close to industrial, entrepreneurial, clinical and regulatory activities to encourage students to consider their studies in a society-wide context. | | |
| Next Steps | | | |